Wuhan General Group (WUHN) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Wuhan General Group $0.00, price $0.00, upside +0.0%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Wuhan General Group (China), Inc., a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Reno, Nevada.
Stock analysis
Wuhan General Group (WUHN) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0002, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Wuhan General Group reported revenue of $14.2K in FY2021 versus $110M in FY2010, a compound −55.7%/yr. Reported net income was −$1.7M in FY2021.
Key figures
Market cap $11.0K · Net margin −13.2% · Return on equity −8.8% · Return on assets (EBIT) −90.5% · Operating margin −2.8% · Free cash flow −$1.7M · Net cash $23.8K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 60% below its 52-week high and 100% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at 0%, WUHN screens cheaper than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−57.4%
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.6%
’06
’07
’08
’09
’10
’11
’12
’20
’21
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
22.3% (2006) → −11,882.9% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2021 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 590 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside+0.0% · Above median
Profitability
Return on assets−0.5% · Bottom 25%
Net margin (TTM)−13.2% · Bottom 25%
Operating margin (TTM)−2.8% · Bottom 25%
Growth and dividend
Revenue growth0.0% · Below median
Balance sheet
Debt / equity10.48× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Wuhan General Group Fair Value". https://www.fairvalue-calculator.com/stock/WUHN
Frequently asked questions
Is Wuhan General Group (WUHN) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.0002 versus a price of $0.0002, about +0% upside (fairly valued).
What is the fair value of WUHN?
Our model-based fair value for Wuhan General Group is $0.0002 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.0002.
What is the quality score of WUHN?
Wuhan General Group has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Wuhan General Group (WUHN)?
Our model-based price target is the fair value of $0.0002 (as of Oct 3, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Wuhan General Group stock forecast for 2026?
Our models put fair value at $0.0002, about +0% upside versus a price of $0.0002 (fairly valued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of Wuhan General Group (WUHN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Wuhan General Group it is $0.0002 per share (as of Oct 3, 2026), against a price of $0.0002. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Wuhan General Group stock overvalued or undervalued in 2026?
As of Oct 3, 2026, WUHN trades below its calculated fair value: price $0.0002, fair value $0.0002, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of WUHN?
No. The price is what the market pays today ($0.0002); the fair value is what the company's own numbers justify ($0.0002). For Wuhan General Group the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Wuhan General Group worth?
The market values Wuhan General Group at about $11.0K (market capitalisation, as of Oct 3, 2026). Per share that is $0.0002; our models calculate a fair value of $0.0002 per share.
How solid is the balance sheet of Wuhan General Group (WUHN)?
Balance-sheet figures for Wuhan General Group (as of Oct 3, 2026): return on equity −8.8%, debt of 10.48 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is WUHN from its 52-week high?
Wuhan General Group trades at $0.0002, about 60% below its 52-week high of $0.0005 and 100% above the low of $0.0001 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0002 is for.
Which stocks are comparable to Wuhan General Group?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Wuhan General Group stock attractive at the current price?
The data as of Oct 3, 2026: price $0.0002, calculated fair value $0.0002 (+0%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of WUHN calculated?
We run Wuhan General Group through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0002, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.3 % above its aggregate fair value. Wuhan General Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Wuhan General Group (WUHN)?
The closing price on Oct 2, 2026 was $0.0002. Our model-based fair value is $0.0002, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Wuhan General Group right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Wuhan General Group
How large is the market capitalisation of Wuhan General Group (WUHN)?
The market capitalisation of Wuhan General Group is $11.0K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of Wuhan General Group (WUHN)?
The net margin of Wuhan General Group is −13.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Wuhan General Group (WUHN)?
The return on equity (ROE) of Wuhan General Group is −8.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Wuhan General Group (WUHN)?
On an EBIT basis the return on assets of Wuhan General Group is −90.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Wuhan General Group (WUHN)?
The operating margin of Wuhan General Group is −2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Wuhan General Group (WUHN) generate?
The free cash flow of Wuhan General Group is −$1.7M (fiscal year 2021). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Wuhan General Group (WUHN) hold?
Wuhan General Group holds more cash than debt, $23.8K net (fiscal year 2021). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Wuhan General Group in the live analysis
One click puts Wuhan General Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 3, 2026